Technology Transfer Office

New compound for in cellulo assay predicting platinum salts efficacy

Institut Curie
New compound for in cellulo assay predicting platinum salts efficacy avaiblable for licence
 Plateforme de criblage phénotypique Biophenics
Plateforme de criblage phénotypique Biophenics dirigée par Elaine Del Nery dans le département de Recherche translationnelle. Cette plateforme repose sur l'expertise de l'Institut Curie en biologie cellulaire. Grâce à l'automatisation de la prise d'images couplées à des algorithmes d'analyse d'images, la biologie cellulaire est mise au service de la validation de cibles et de l'identification de molécules chimiques actives plus sélectives.


  • Prediction of platinum resistance
  • Screening method for overcoming platinum resistance


We have developed a technology that chemically label platinated DNA lesions in cells pre-treated with the native platinum-based drug using click chemistry. This technology can be exploited in several settings and for different purposes.

  • Ex vivo: treating tumors from patients either just after surgery and/or freshly defrosted. The protocol should be broadly applicable and easy to use with a result within 5 hours.
  • In vitro: selecting compounds that modulate and enhance the potency of platinum drugs using visual detection of labelled platinated DNA lesions, monitoring DNA targets and associated proteins by means of deep sequencing and quantitative proteomics.


Platinating compounds such as cisplatin, carboplatin, and oxaliplatin are still front-line clinical therapies and constitute part of the treatment regimen for patients with many types of cancers, including head and neck, testicular, ovarian, cervical, lung, colorectal and relapsed lymphoma. Patients usually have a good initial response to cisplatin-based chemotherapy but later relapse, because the development of cisplatin resistance, either acquired or intrinsic, markedly reduces its clinical effectiveness. Therefore, any new method or tool useful for predicting or studying cisplatin resistance or for identifying a molecule capable of overcoming the cisplatin resistance would be of interest in this regard.

Competitive advantages

  • Protocol could be used in a non-specific environment (i.e in Pathology Dpt)
  • Results available in 5 hours

Intellectual Property

EP 15 30 7009

R&D Status

R&D status Poc In vivo

Research tool
Platinum salts